Verrica Pharmaceuticals Inc. (VRCA) financial statements (2021 and earlier)

Company profile

Business Address 10 NORTH HIGH STREET
WEST CHESTER, PA 19380
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11910
Cash and cash equivalents11910
Other undisclosed current assets575681
Total current assets:686591
Noncurrent Assets
Operating lease, right-of-use asset20
Property, plant and equipment320
Deposits noncurrent assets 10
Other noncurrent assets2  
Total noncurrent assets:731
TOTAL ASSETS:746892
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities232
Accounts payable011
Accrued liabilities022
Employee-related liabilities1  
Interest and dividends payable0  
Deferred revenue1 
Debt350 
Due to related parties  0
Other undisclosed current liabilities1  
Total current liabilities:3932
Noncurrent Liabilities
Long-term debt and lease obligation20 
Operating lease, liability20
Other undisclosed noncurrent liabilities(2)  
Total noncurrent liabilities:20 
Total liabilities:4132
Stockholders' equity
Stockholders' equity attributable to parent336589
Common stock000
Additional paid in capital137127123
Accumulated other comprehensive income (loss)00(0)
Accumulated deficit(104)(61)(33)
Stockholders' equity note, subscriptions receivable (0) 
Total stockholders' equity:336589
TOTAL LIABILITIES AND EQUITY:746892

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Operating expenses(40)(30)(22)
Other operating expense, net
(Other Expenses)
(0)(0)(0)
Other undisclosed operating income000
Operating loss:(40)(30)(22)
Nonoperating income (expense)(3)21
Investment income, nonoperating121
Interest and debt expense(3)  
Loss from continuing operations before income taxes:(46)(28)(21)
Income tax benefit2  
Loss before gain (loss) on sale of properties:(43)(28)(21)
Other undisclosed net income1  
Net loss available to common stockholders, diluted:(43)(28)(21)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(43)(28)(21)
Comprehensive loss:(43)(28)(21)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(43)(28)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: